[Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast].
Forty-eight patients with inflammatory breast cancer were treated by an induction regimen with cyclophosphamide (1200 mg/m2), and epirubicin (75 mg/m2). Four to six courses were given every two weeks, whatever the absolute leukocyte counts, before mastectomy, loco-regional radiation, and conventional, or reinforced, for selected patients, chemotherapy. Main toxicity was leukopenia, with grade IV in 25% of cases. However, febrile neutropenia was rare, and relative dose intensity was 102% after four courses, and 97% after six courses. Complete disappearance of inflammatory signs was observed in 90% of patients. Three patients had a pathological complete response, and ten patients had negative axillary lymph nodes. Furthermore, 13 patients had a major pathological response. With a median follow-up of 42 months, progression-free survival and overall survival are 48% and 66%, respectively.
Culine
S
S
Service d'oncologie médicale, hôpital Saint-Louis, Paris, France.
Extra
J M
JM
Espie
M
M
Bourstyn
E
E
Dieras
V
V
Giacchetti
S
S
Maylin
C
C
De Rocquancourt
A
A
Morvan
F
F
Marty
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D015409:Mastectomy, Radical; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
D015251:Epirubicin; D003520:Cyclophosphamide
Résultats prometteurs d'une chimiothérapie bimensuelle avec cyclophosphamide et épirubicine à forte dose dans le traitement d'induction du cancer du sein inflammatoire.